Does cognitive function improve with quetiapine in comparison to haloperidol? (Q43819115)

27 November 2017

title

Does cognitive function improve with quetiapine in comparison to haloperidol? (English)

1 reference

27 November 2017

John Newcomer

2

1 reference

ORCID Public Data File 2021

author name string

Dawn I Velligan

1

1 reference

27 November 2017

Joseph Pultz

3

1 reference

27 November 2017

John Csernansky

4

1 reference

27 November 2017

Anne L Hoff

5

1 reference

27 November 2017

Roderick Mahurin

6

1 reference

27 November 2017

Alexander L Miller

7

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

27 November 2017

published in

Schizophrenia Research

1 reference

27 November 2017

volume

53

1 reference

27 November 2017

issue

3

1 reference

27 November 2017

page(s)

239-248

1 reference

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900268-7

7 January 2021

Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900268-7

7 January 2021

Visuospatial working memory in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900268-7

7 January 2021

Cognitive deficits in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900268-7

7 January 2021

The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900268-7

7 January 2021

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900268-7

7 January 2021

Neuropsychological functioning of first-episode schizophreniform patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900268-7

7 January 2021

A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900268-7

7 January 2021

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900268-7

7 January 2021

Quetiapine ('Seroquel'); an effective and well-tolerated atypical antipsychotic

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900268-7

7 January 2021

Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900268-7

7 January 2021

Frontal/executive impairments in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900268-7

7 January 2021

Cognitive function in schizophrenia--do neuroleptics make a difference?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900268-7

7 January 2021

Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900268-7

7 January 2021

Information processing and attentional functioning in the developmental course of schizophrenic disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900268-7

7 January 2021

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900268-7

7 January 2021

Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900268-7

7 January 2021

The cognitive efficacy of atypical antipsychotics in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900268-7

7 January 2021

Seroquel and cognitive improvement in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900268-7

7 January 2021

The functional significance of symptomatology and cognitive function in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900268-7

7 January 2021

Cognitive dysfunction in schizophrenia followed up over 5 years, and its longitudinal relationship to the emergence of tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900268-7

7 January 2021

10.1016/S0920-9964(01)00268-7

Identifiers

DOI

1 reference

27 November 2017

1 reference